Ensifentrine Brings First New COPD Mechanism in Over a Decade
Start here
Ensifentrine is an inhaled dual PDE3/PDE4 inhibitor, delivered as 3 mg twice daily by nebulisation, that raises cAMP to produce both bronchodilation and anti-inflammatory effects. The FDA approved it in 2024 as the first COPD drug with a new mechanism of action in more than ten years, and it is positioned as add-on therapy on top of LAMA/LABA/ICS treatment. Support came from the ENHANCE 1 and 2 trials, each enrolling about 700 patients, where FEV1 improved by 87 and 94 mL respectively. The exacerbation endpoint in ENHANCE 2 did not reach significance, a result attributed to high dropout in the placebo group. Open questions include how the drug performs on exacerbation reduction in real-world use.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- youtube.comEnsifentrine: First Novel-Mechanism COPD Drug in Over a Decade, Explained
Ensifentrine, an inhaled dual PDE3/PDE4 inhibitor given as 3 mg twice daily by nebulisation, received FDA approval in 2024 as the first COPD drug with a new mechanism in more than ten years. It raises cAMP, producing bronchodilation and anti-inflammatory effects, and is positioned as add-on therapy to LAMA/LABA/ICS. In the ENHANCE 1 and 2 trials of about 700 patients each, FEV1 improved by 87 and 94 mL, while the exacerbation endpoint in ENHANCE 2 missed significance owing to high placebo-group dropout.
Heat trend for this story
Heat now 9·Peak in the comparable set 10 (Oct 18 04:00)·Change over 24h in the comparable set –
The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's heat; the left and right arrow keys work too.